

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Colorectal cancer	Checkpoint kinase 1 (Chk1)	<p>Mouse studies identified an isoquinoline-based Chk1 inhibitor called SAR-020106 that could help treat colorectal cancer. In a mouse xenograft model of human colorectal cancer, the lead Chk1 inhibitor plus irinotecan resulted in greater tumor growth inhibition than either compound alone. Next steps could include evaluating SAR-020106 in additional animal models of cancer.</p> <p>Sareum Holdings plc has oral Chk1 inhibitors in preclinical development for various cancers including colorectal cancer.</p> <p>At least six other companies have Chk1 inhibitors in Phase I/II testing or earlier to treat cancer.</p> <p>SciBX 4(48); doi:10.1038/scibx.2011.1350 Published online Dec. 15, 2011</p>	Patent and licensing status unavailable	<p>Reader, J.C. <i>et al. J. Med. Chem.</i>; published online Nov. 23, 2011; doi:10.1021/jm2007326</p> <p>Contact: Ian Collins, The Institute of Cancer Research, Surrey, U.K. e-mail: ian.collins@icr.ac.uk</p> <p>Contact: John C. Reader, Sareum Holdings plc, Cambridge, U.K. e-mail: john.reader@sareum.co.uk</p>